17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Cell culture and mouse studies suggest inhibiting miR-23b and miR-218 could help treat DM1. In myoblast cells from a DM1 patient, miR-23b and miR-218 antagomirs decreased disease-associated splicing defects...
08:00 , Nov 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer MicroRNA-23b (miR-23b) Patient sample and mouse studies suggest increasing miR-23b signaling could help treat prostate cancer. In patient samples, miR-23b expression was lower...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Lupus; rheumatoid arthritis (RA); multiple sclerosis (MS) MicroRNA-23b (miR-23b) Patient sample and mouse studies suggest agonizing miR-23b could help treat autoimmune diseases such as...